NCT05173831View on ClinicalTrials.gov

Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

September 30, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

PTSD

Interventions

DRUG

Midomafetamine

Initial dose of 120 mg midomafetamine HCl and optional supplemental dose of 60 mg 1.5 to 2 hours later

BEHAVIORAL

Therapy

Manualized therapy performed by therapist team

Sponsors

Lead Sponsor

Lykos Therapeutics

All Listed Sponsors

lead

Lykos Therapeutics

INDUSTRY

NCT05173831 - Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans | Biotech Hunter | Biotech Hunter